Syncona performance slips in December quarter as Nightstar shares fall

Writer, Stock Market Wire
Wednesday, February 13, 2019 - 07:21

Healthcare company investor Syncona said its performance slipped over the December quarter due to a fall in the share price of portfolio company Nightstar.

For the three months through December, Syncona posted a total return of negative 6.6%.

However, over the nine months through December the company posted a total return of 23.9%.

Other portfolio company, Blue Earth Diagnostics, showed good sales momentum with US unit sales of Axumin for the treatment of prostate cancer rising 17% to of 7,575.

Nightstar, meanwhile, announced plans to initiate a phase 2/3 expansion study in its second programme for treating vision impairment.

'We are pleased with the strong progress across our companies over the period,' chief executive Martin Murphy said.

'As we look forward, we continue to see a strong pipeline of exciting opportunities where we can continue to build globally competitive companies around exceptional science.'

Related content

Syncona invests £48m in retinal therapy company Gyroscope Therapeutic.

Healthcare company investor Syncona said it had invested £48m in retinal gene therapy group Gyroscope Therapeutic.

The investment came as part of a £50.4m Series...

Tue, 03/09/2019 - 07:27

Syncona valuation jumps in June quarter after asset sales

Health company investor Syncona said its net asset value rose by 57.1% in the June quarter after it sold investments Blue Earth Diagnostics and Nightstar....

Mon, 12/08/2019 - 07:11

Syncona completes sale of Blue Earth Diagnostics for $476.3m

Life science investment trust Syncona said it had completed the sale of its portfolio company Blue Earth Diagnostics to Bracco Imaging for $476.3m (£390.2m).


Thu, 01/08/2019 - 09:38

Surf the ‘third wave’ of healthcare innovation with Syncona


Life science focused investment trust Syncona (SYNC) generated an excellent net asset value (NAV) total return of 37.9% for the year to 31...

Thu, 11/07/2019 - 00:00

Syncona sees surge in net asset value growth


INVESTMENT TRUST Syncona (SYNC) has reported 38% growth in net asset value (NAV) for the year ended 31 March. It invests in life...

Thu, 20/06/2019 - 00:00